✉news BusinessRetail first seen 3 d ago, last 3 d ago, peak #14

ImmunityBio slides despite Anktiva FDA win as investors wait

Original: IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk

ImmunityBio (IBRX) shares are heading for a weekly decline even after a positive FDA development for Anktiva, the company's cancer immunotherapy. Retail investors remain cautious, with attention focused on remarks expected from founder Patrick Soon-Shiong regarding a trial. Investors appear unconvinced the regulatory win is enough to offset concerns about the company's clinical pipeline and spending.

Why now: A regulatory win for Anktiva failed to lift the stock, prompting debate over whether the founder's upcoming trial comments could change sentiment.

ImmunityBioIBRXAnktivaFDAPatrick Soon-Shiong

Open on news →

Rank over time, top of the chart is #1. 3 snapshots from 3 d ago to 3 d ago.

Evidence

• IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk · Stocktwits
• IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk · Yahoo Finance

API: https://socialmediatrends-api.osmike.com/v1/trends/2326269